Literature DB >> 18362888

Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling.

Y-J Jeon1, I K Kim, S-H Hong, H Nan, H-J Kim, H-J Lee, E S Masuda, O Meyuhas, B-H Oh, Y-K Jung.   

Abstract

TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a potent inducer of apoptosis in tumor cells and holds a promise as a therapeutic agent against cancer. To elucidate the death signaling evoked by TRAIL, we performed a functional genetic screening and rescued TRAIL-resistant Jurkat clones harboring ribosomal protein S6 (rpS6) cDNA in anti-sense frame. Reduction of rpS6 expression in Jurkat and HeLa cells attenuated apoptosis induced by TRAIL, but not those by other cell death signals, including tumor necrosis factor-alpha and cycloheximide, etoposide, doxorubicin, tunicamycin and staurosporine. Death receptor (DR) 4, but not DR5, was downregulated in rpS6 knockdown cells. Conversely, the sensitivity to TRAIL was increased by the ectopic expression of wild-type rpS6 and further by phospho-defective rpS6 mutant (S6-SS235,6AA), but not by phospho-mimic rpS6 mutant (S6-SS235,6DD). Also, unphosphorylatable rpS6 knock-in mouse embryo fibroblasts (rpS6(P-/-) MEFs) were more sensitive to TRAIL than control MEFs. In addition, SKHep-1 tumor cells, which express less phospho-rpS6 and are more sensitive to TRAIL than other tumor cells, became effectively desensitized to TRAIL after rpS6 knockdown. These results suggest that rpS6, especially in its unphosphorylated form, is a selective mediator of TRAIL-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362888     DOI: 10.1038/onc.2008.73

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Alterations in Phosphorylation of Hepatocyte Ribosomal Protein S6 Control Plasmodium Liver Stage Infection.

Authors:  Elizabeth K K Glennon; Laura S Austin; Nadia Arang; Heather S Kain; Fred D Mast; Kamalakannan Vijayan; John D Aitchison; Stefan H I Kappe; Alexis Kaushansky
Journal:  Cell Rep       Date:  2019-03-19       Impact factor: 9.423

Review 2.  Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications.

Authors:  Wei Wang; Subhasree Nag; Xu Zhang; Ming-Hai Wang; Hui Wang; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2014-08-28       Impact factor: 12.944

3.  Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals.

Authors:  Terence O'Reilly; Paul Mj McSheehy
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

4.  Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells.

Authors:  Y Oh; Y-J Jeon; G-S Hong; I Kim; H-N Woo; Y-K Jung
Journal:  Cell Death Differ       Date:  2012-01-13       Impact factor: 15.828

5.  Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival.

Authors:  Luis Eduardo Machado; Arthur William Alvarenga; Fernanda Ferreira da Silva; Martín Roffé; Maria Dirlei Begnami; Luís Fernando Bleggi Torres; Isabela Werneck da Cunha; Vilma Regina Martins; Glaucia Noeli Maroso Hajj
Journal:  J Histochem Cytochem       Date:  2018-01-12       Impact factor: 2.479

Review 6.  Ribosomal proteins induce stem cell-like characteristics in glioma cells as an "extra-ribosomal function".

Authors:  Takuichiro Hide; Ichiyo Shibahara; Madoka Inukai; Ryota Shigeeda; Yuki Shirakawa; Hirofumi Jono; Naoki Shinojima; Akitake Mukasa; Toshihiro Kumabe
Journal:  Brain Tumor Pathol       Date:  2022-05-05       Impact factor: 3.298

Review 7.  Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

Authors:  Yong Weon Yi; Kyu Sic You; Jeong-Soo Park; Seok-Geun Lee; Yeon-Sun Seong
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

8.  Normalization with genes encoding ribosomal proteins but not GAPDH provides an accurate quantification of gene expressions in neuronal differentiation of PC12 cells.

Authors:  Lihan Zhou; Qing-En Lim; Guoqiang Wan; Heng-Phon Too
Journal:  BMC Genomics       Date:  2010-01-29       Impact factor: 3.969

9.  Intracellular parasitism with Toxoplasma gondii stimulates mammalian-target-of-rapamycin-dependent host cell growth despite impaired signalling to S6K1 and 4E-BP1.

Authors:  Yubao Wang; Louis M Weiss; Amos Orlofsky
Journal:  Cell Microbiol       Date:  2009-02-27       Impact factor: 3.715

10.  Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer - A retrospective pilot analysis and viewpoint.

Authors:  Jyoti Bajpai; Anant Ramaswamy; Arun Chandrasekharan; Surya Mishra; Tanuja Shet; Sudeep Gupta; R A Badwe
Journal:  South Asian J Cancer       Date:  2017 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.